BioSpace News Archive

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, executive chairman, is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 2:00 p.m. Eastern Time.

Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2019, after the market closes on February 18, 2020

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced the appointment of James Bucher as Senior Sales Consultant

VectivBio AG, a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases, today announced it has appointed Kevin Harris as chief commercial officer.

IQ4I Research & Consultancy published a new report on “Molecular Diagnostics Global Market – Forecast To 2026" .

Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at the BIO CEO & Investor Conference taking place February 10-11, 2020 at the New York Marriott Marquis.

Epic Sciences, Inc. announced today it will present two abstracts at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium to be held in San Francisco, February 13-15, 2020. The abstracts feature two analyses of the PROPHECY trial cohort

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its New Drug Application (NDA) seeking accelerated approval of avapritinib for the treatment of adults with fourth-line gastrointestinal stromal tumor (GIST)

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its third quarter fiscal year 2020, ended December 31, 2019, at 4:15pm Eastern time on Monday, February 10, 2020.

Dalrada Health, a wholly-owned subsidiary of Dalrada Financial Corp. (OTC Pink: DFCO), is pleased to announce the filing of a provisional patent with the United States Patent and Trademark Office (USPTO) for their product designed to screen for cervical cancer.